CTI BioPharma Stock Price, News & Analysis (NASDAQ:CTIC)

$2.51 -0.02 (-0.79 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$2.53
Today's Range$2.45 - $2.52
52-Week Range$2.45 - $6.48
Volume254,100 shs
Average Volume161,570 shs
Market Capitalization$108.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.54

About CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma logoCTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTIC
CUSIPN/A
Phone206-282-7100

Debt

Debt-to-Equity Ratio0.26%
Current Ratio2.19%
Quick Ratio2.17%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$57.40 million
Price / Sales1.88
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book9.30

Profitability

Trailing EPS($1.19)
Net Income$-52,000,000.00
Net Margins-96.91%
Return on Equity-209.67%
Return on Assets-50.35%

Miscellaneous

Employees100
Outstanding Shares42,970,000

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma shares reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. The biopharmaceutical company earned $1.71 million during the quarter, compared to the consensus estimate of $0.30 million. CTI BioPharma had a negative net margin of 96.91% and a negative return on equity of 209.67%. View CTI BioPharma's Earnings History.

When will CTI BioPharma make its next earnings announcement?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for CTI BioPharma.

Where is CTI BioPharma's stock going? Where will CTI BioPharma's stock price be in 2017?

1 Wall Street analysts have issued 12-month price objectives for CTI BioPharma's shares. Their predictions range from $7.50 to $7.50. On average, they anticipate CTI BioPharma's share price to reach $7.50 in the next year. View Analyst Ratings for CTI BioPharma.

Who are some of CTI BioPharma's key competitors?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:

  • Laurent Fischer M.D., Chairman of the Board (Age 52)
  • Adam R. Craig M.D., Ph.D., President, Chief Executive Officer, Director (Age 51)
  • David H. Kirske, Chief Financial Officer, Executive Vice President (Age 62)
  • Bruce J. Seeley, Chief Operating Officer (Age 53)
  • Jack W. Singer M.D., Interim Chief Medical Officer, Global Head of Translational Medicine, Executive Vice President, Chief Scientific Officer (Age 72)
  • Nancy L. Boman Ph.D., Senior Vice President of Clinical Development and Regulatory Affairs
  • Monique M. Greer, Senior Vice President of Corporate Communications and Investor Relations (Age 48)
  • Michael A. Metzger, Director (Age 45)
  • Matthew Perry, Director
  • David Ross Parkinson M.D., Independent Director (Age 67)

Who owns CTI BioPharma stock?

CTI BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (2.31%), JPMorgan Chase & Co. (0.20%) and OxFORD Asset Management LLP (0.12%). Company insiders that own CTI BioPharma stock include Jack W Singer, James A Bianco, Matthew Plunkett, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Who sold CTI BioPharma stock? Who is selling CTI BioPharma stock?

CTI BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. View Insider Buying and Selling for CTI BioPharma.

Who bought CTI BioPharma stock? Who is buying CTI BioPharma stock?

CTI BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and OxFORD Asset Management LLP. View Insider Buying and Selling for CTI BioPharma.

How do I buy CTI BioPharma stock?

Shares of CTI BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTI BioPharma stock can currently be purchased for approximately $2.51.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $108.71 million and generates $57.40 million in revenue each year. The biopharmaceutical company earns $-52,000,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. CTI BioPharma employs 100 workers across the globe.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 600, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (CTIC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CTI BioPharma (NASDAQ:CTIC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.502.502.501.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$7.50$5.70
Price Target Upside: 131.48% upside131.48% upside131.48% upside62.86% upside

CTI BioPharma (NASDAQ:CTIC) Consensus Price Target History

Price Target History for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ:CTIC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Jefferies GroupInitiated CoverageBuy -> Buy$7.50HighView Rating Details
8/29/2016Piper Jaffray CompaniesReiterated RatingNeutral$7.50N/AView Rating Details
2/10/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
2/10/2016WallachBeth CapitalDowngradeHold -> SellN/AView Rating Details
2/8/2016S&P Equity ResearchLower Price Target$4.80 -> $3.90N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

CTI BioPharma (NASDAQ:CTIC) Earnings History and Estimates Chart

Earnings by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ CTIC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.30)N/AView Earnings Details
11/6/2017Q3 2017($0.32)($0.28)$0.30 million$1.71 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.60)$0.03$22.23 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.70)($0.71)$0.75 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.70)($0.23)$9.14 millionViewListenView Earnings Details
8/4/2016Q2($0.10)($0.07)$7.36 millionViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01$36.48 millionViewN/AView Earnings Details
2/16/2016Q4($0.18)($0.13)$11.32 millionViewN/AView Earnings Details
11/5/2015Q315($0.12)($0.19)$18.89 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.10)($0.19)$12.77 million$1.10 millionViewListenView Earnings Details
5/6/2015Q115($0.14)($0.16)$9.84 million$2.73 millionViewListenView Earnings Details
3/12/2015Q414($0.18)($0.27)$2.48 million$17.80 millionViewListenView Earnings Details
10/29/2014Q3$0.03$0.03$21.52 million$39.53 millionViewListenView Earnings Details
8/4/2014Q2($0.12)($0.19)$11.79 million$1.34 millionViewListenView Earnings Details
4/29/2014Q114($0.20)($0.20)$1.10 million$1.40 millionViewN/AView Earnings Details
3/4/2014Q4($0.16)$0.08$1.26 million$32.90 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.20)($0.20)$1.00 millionViewListenView Earnings Details
11/1/2012Q312($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

CTI BioPharma (NASDAQ:CTIC) Earnings Estimates

2017 EPS Consensus Estimate: ($0.62)
2018 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.30)($0.30)($0.30)
Q1 20181($0.34)($0.34)($0.34)
Q2 20181($0.34)($0.34)($0.34)
Q3 20181($0.68)($0.68)($0.68)
Q4 20181($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CTI BioPharma (NASDAQ:CTIC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CTI BioPharma (NASDAQ CTIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.08%
Institutional Ownership Percentage: 42.83%
Insider Trades by Quarter for CTI BioPharma (NASDAQ:CTIC)
Institutional Ownership by Quarter for CTI BioPharma (NASDAQ:CTIC)

CTI BioPharma (NASDAQ CTIC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2017Richard L LoveDirectorSell14,600$3.21$46,866.00View SEC Filing  
6/24/2016James A BiancoCEOSell10,000$0.37$3,700.00View SEC Filing  
5/27/2016James A BiancoCEOSell10,000$0.45$4,500.00View SEC Filing  
4/29/2016James A BiancoCEOSell10,000$0.52$5,200.00View SEC Filing  
3/28/2016James A BiancoCEOSell10,000$0.49$4,900.00View SEC Filing  
3/21/2016James A BiancoCEOSell318,169$0.55$174,992.95View SEC Filing  
3/4/2016Matthew PlunkettEVPSell10,000$0.59$5,900.00View SEC Filing  
2/26/2016Jack W SingerEVPSell15,000$0.63$9,450.00View SEC Filing  
2/26/2016James A BiancoCEOSell10,000$0.63$6,300.00View SEC Filing  
2/16/2016James A BiancoCEOSell100,000$0.42$42,000.00View SEC Filing  
2/4/2016Matthew PlunkettEVPSell10,000$1.15$11,500.00View SEC Filing  
1/29/2016Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
1/29/2016James A BiancoCEOSell10,000$1.20$12,000.00View SEC Filing  
1/8/2016Value Fund L P BiotechnologyInsiderBuy1,001,327$1.22$1,221,618.94View SEC Filing  
1/4/2016Matthew PlunkettEVPSell10,000$1.21$12,100.00View SEC Filing  
12/30/2015James A. BiancoCEOSell110,000$1.26$138,600.00View SEC Filing  
12/28/2015James A. BiancoCEOSell10,000$1.29$12,900.00View SEC Filing  
12/18/2015Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
12/4/2015Matthew PlunkettEVPSell10,000$1.00$10,000.00View SEC Filing  
11/27/2015Jack W. SingerEVPSell15,000$1.21$18,150.00View SEC Filing  
11/27/2015James A BiancoCEOSell10,000$1.23$12,300.00View SEC Filing  
11/19/2015Louis A. BiancoEVPSell15,000$1.13$16,950.00View SEC Filing  
10/30/2015James A BiancoCEOSell260,000$1.35$351,000.00View SEC Filing  
10/29/2015Louis A. BiancoEVPSell10,000$1.41$14,100.00View SEC Filing  
10/23/2015Jack W. SingerEVPSell15,000$1.62$24,300.00View SEC Filing  
10/22/2015Louis A BiancoEVPSell10,000$1.58$15,800.00View SEC Filing  
10/5/2015Matthew PlunkettEVPSell10,000$1.52$15,200.00View SEC Filing  
9/30/2015Jack W. SingerEVPSell100,000$1.42$142,000.00View SEC Filing  
9/30/2015James A. BiancoCEOSell600,000$1.43$858,000.00View SEC Filing  
9/30/2015Richard L. LoveDirectorSell13,660$1.45$19,807.00View SEC Filing  
9/29/2015Louis A. BiancoEVPSell170,000$1.41$239,700.00View SEC Filing  
9/25/2015Jack W. SingerEVPSell15,000$1.64$24,600.00View SEC Filing  
9/24/2015Matthew PlunkettEVPSell75,869$1.57$119,114.33View SEC Filing  
9/4/2015Matthew PlunkettEVPSell10,000$1.54$15,400.00View SEC Filing  
8/28/2015Jack W. SingerEVPSell15,000$1.58$23,700.00View SEC Filing  
7/24/2015Jack W SingerEVPSell15,000$1.91$28,650.00View SEC Filing  
7/23/2015Louis A BiancoEVPSell10,000$1.91$19,100.00View SEC Filing  
7/6/2015Matthew PlunkettEVPSell10,000$1.95$19,500.00View SEC Filing  
6/26/2015Jack W SingerEVPSell15,000$2.07$31,050.00View SEC Filing  
6/25/2015Louis A BiancoEVPSell10,000$2.18$21,800.00View SEC Filing  
6/4/2015Matthew PlunkettEVPSell10,000$2.06$20,600.00View SEC Filing  
5/22/2015Jack W SingerEVPSell15,000$1.74$26,100.00View SEC Filing  
5/21/2015Louis A BiancoEVPSell10,000$1.80$18,000.00View SEC Filing  
5/4/2015Matthew PlunkettEVPSell10,000$1.86$18,600.00View SEC Filing  
4/24/2015Jack W SingerEVPSell15,000$1.96$29,400.00View SEC Filing  
4/23/2015Louis A BiancoEVPSell10,000$1.93$19,300.00View SEC Filing  
4/6/2015Matthew PlunkettEVPSell16,569$1.88$31,149.72View SEC Filing  
3/23/2015James A BiancoCEOSell175,199$1.95$341,638.05View SEC Filing  
3/23/2015Matthew PlunkettEVPSell59,130$1.96$115,894.80View SEC Filing  
3/20/2015Louis A BiancoEVPSell63,000$1.94$122,220.00View SEC Filing  
2/27/2015Jack W SingerEVPSell15,000$2.35$35,250.00View SEC Filing  
2/5/2015Louis A BiancoEVPSell10,000$2.22$22,200.00View SEC Filing  
2/4/2015Matthew PlunkettEVPSell12,000$2.22$26,640.00View SEC Filing  
1/8/2015Louis A BiancoEVPSell10,000$2.32$23,200.00View SEC Filing  
1/5/2015Matthew PlunkettEVPSell12,000$2.36$28,320.00View SEC Filing  
12/19/2014James A BiancoCEOSell40,000$2.44$97,600.00View SEC Filing  
12/4/2014Louis A BiancoEVPSell10,000$2.25$22,500.00View SEC Filing  
11/6/2014Louis A BiancoEVPSell10,000$2.37$23,700.00View SEC Filing  
10/6/2014Matthew PlunkettEVPSell12,000$2.39$28,680.00View SEC Filing  
9/23/2014Matthew PlunkettEVPSell103,635$2.56$265,305.60View SEC Filing  
9/22/2014James A BiancoCEOSell307,068$2.53$776,882.04View SEC Filing  
9/22/2014Matthew PlunkettEVPSell51,817$2.58$133,687.86View SEC Filing  
9/19/2014Louis A BiancoEVPSell145,000$2.59$375,550.00View SEC Filing  
9/4/2014Matthew PlunkettEVPSell27,301$2.48$67,706.48View SEC Filing  
8/15/2014James A BiancoCEOSell40,000$2.54$101,600.00View SEC Filing  
8/4/2014Matthew PlunkettEVPSell12,000$2.48$29,760.00View SEC Filing  
7/10/2014Louis A BiancoEVPSell10,000$2.73$27,300.00View SEC Filing  
7/7/2014Matthew PlunkettEVPSell12,000$2.89$34,680.00View SEC Filing  
6/27/2014James A BiancoCEOSell50,000$2.84$142,000.00View SEC Filing  
6/5/2014Louis A BiancoEVPSell10,000$2.97$29,700.00View SEC Filing  
5/1/2014Louis BiancoEVPSell10,000$2.91$29,100.00View SEC Filing  
3/28/2014Vartan GregorianDirectorSell82,000$3.41$279,620.00View SEC Filing  
3/25/2014Phillip Phd NudelmanDirectorSell100,000$3.56$356,000.00View SEC Filing  
3/24/2014Jack SingerEVPSell60,000$3.47$208,200.00View SEC Filing  
3/21/2014James BiancoCEOSell395,000$3.83$1,512,850.00View SEC Filing  
3/21/2014Matthew PlunkettEVPSell170,000$3.73$634,100.00View SEC Filing  
3/7/2014Fred TellingDirectorSell72,095$3.75$270,356.25View SEC Filing  
9/23/2013James A BiancoCEOSell130,551$1.50$195,826.50View SEC Filing  
8/30/2013James A BiancoCEOSell25,925$1.08$27,999.00View SEC Filing  
8/9/2013James A BiancoCEOSell40,000$1.07$42,800.00View SEC Filing  
8/7/2013Mary Oneil MundingerDirectorSell125,000$1.06$132,500.00View SEC Filing  
8/6/2013Phillip M Phd NudelmanDirectorSell50,000$1.09$54,500.00View SEC Filing  
7/26/2013James A BiancoCEOSell25,688$1.09$27,999.92View SEC Filing  
6/28/2013James A BiancoCEOSell26,053$1.08$28,137.24View SEC Filing  
6/5/2013Jack W SingerEVPSell10,000$1.26$12,600.00View SEC Filing  
5/31/2013James A BiancoCEOSell28,000$1.22$34,160.00View SEC Filing  
5/31/2013Louis A BiancoEVPSell33,712$1.24$41,802.88View SEC Filing  
5/30/2013Fred TellingDirectorSell64,798$1.24$80,349.52View SEC Filing  
5/24/2013Richard L LoveDirectorSell23,000$1.21$27,830.00View SEC Filing  
5/10/2013James A BiancoCEOSell25,000$1.16$29,000.00View SEC Filing  
5/9/2013Louis A BiancoEVPSell50,000$1.15$57,500.00View SEC Filing  
3/11/2013Jack W SingerEVPSell13,000$1.28$16,640.00View SEC Filing  
8/10/2012James A BiancoCEOSell10,000$0.42$4,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CTI BioPharma (NASDAQ CTIC) News Headlines

Source:
DateHeadline
35 Stocks Moving In Wednesdays Pre-Market Session - Benzinga35 Stocks Moving In Wednesday's Pre-Market Session - Benzinga
www.benzinga.com - November 29 at 9:40 AM
Is CTI BioPharma Corp (CTIC) Undervalued?Is CTI BioPharma Corp (CTIC) Undervalued?
finance.yahoo.com - November 20 at 6:39 PM
ETFs with exposure to CTI BioPharma Corp. : November 10, 2017ETFs with exposure to CTI BioPharma Corp. : November 10, 2017
finance.yahoo.com - November 10 at 5:33 PM
CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference - PR Newswire (press release)CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 10 at 7:01 AM
FY2017 Earnings Forecast for CTI BioPharma Corp. Issued By Jefferies Group (CTIC)FY2017 Earnings Forecast for CTI BioPharma Corp. Issued By Jefferies Group (CTIC)
www.americanbankingnews.com - November 9 at 8:16 AM
CTI BioPharmas (CTIC) CEO Adam Craig on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaCTI BioPharma's (CTIC) CEO Adam Craig on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 11:26 PM
CTI BioPharma to Present at the Jefferies 2017 London Healthcare ConferenceCTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 8 at 5:22 AM
Edited Transcript of CTIC earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of CTIC earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 6:03 AM
EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q3 Earnings ReportEARNINGS SUMMARY: Details of CTI BioPharma Corp. Q3 Earnings Report
www.rttnews.com - November 7 at 12:00 AM
CTI BioPharma Corp. (CTIC) Announces  Earnings Results, Beats Estimates By $0.04 EPSCTI BioPharma Corp. (CTIC) Announces Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - November 6 at 11:07 PM
CTI BioPharma Reports Third Quarter 2017 Financial Results - PR Newswire (press release)CTI BioPharma Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 6 at 6:57 PM
CTI BioPharma Corp. to Host Earnings CallCTI BioPharma Corp. to Host Earnings Call
finance.yahoo.com - November 6 at 6:57 PM
CTI BioPharma Reports Third Quarter 2017 Financial ResultsCTI BioPharma Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 6:57 PM
CTI BioPharma reports 3Q lossCTI BioPharma reports 3Q loss
finance.yahoo.com - November 6 at 6:57 PM
CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017
finance.yahoo.com - October 30 at 6:13 PM
CTI BioPharma Corp. (CTIC) to Release Earnings on MondayCTI BioPharma Corp. (CTIC) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 1:50 PM
ETFs with exposure to CTI BioPharma Corp. : October 26, 2017ETFs with exposure to CTI BioPharma Corp. : October 26, 2017
finance.yahoo.com - October 26 at 2:34 PM
Analyzing CTI BioPharma Corp. (CTIC) & Its PeersAnalyzing CTI BioPharma Corp. (CTIC) & Its Peers
www.americanbankingnews.com - October 19 at 6:26 AM
ETFs with exposure to CTI BioPharma Corp. : October 16, 2017ETFs with exposure to CTI BioPharma Corp. : October 16, 2017
finance.yahoo.com - October 16 at 6:21 PM
ValuEngine Lowers CTI BioPharma Corp. (CTIC) to Strong SellValuEngine Lowers CTI BioPharma Corp. (CTIC) to Strong Sell
www.americanbankingnews.com - October 11 at 10:26 PM
CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 3 at 6:44 AM
ETFs with exposure to CTI BioPharma Corp. : October 2, 2017ETFs with exposure to CTI BioPharma Corp. : October 2, 2017
finance.yahoo.com - October 3 at 6:44 AM
CTI BioPharma Corp. (CTIC) Director Sells $46,866.00 in StockCTI BioPharma Corp. (CTIC) Director Sells $46,866.00 in Stock
www.americanbankingnews.com - October 2 at 8:02 PM
CTI BioPharma Corp. (CTIC) Short Interest Down 23.5% in AugustCTI BioPharma Corp. (CTIC) Short Interest Down 23.5% in August
www.americanbankingnews.com - September 17 at 1:20 AM
CTI BioPharma Corp. Forecasted to Post Q3 2017 Earnings of ($0.32) Per Share (CTIC)CTI BioPharma Corp. Forecasted to Post Q3 2017 Earnings of ($0.32) Per Share (CTIC)
www.americanbankingnews.com - September 14 at 7:33 AM
Pre-Open Movers 09/12: (ALDX) (QTNT) (CTIC) Higher; (SAGE) (ICPT) (HIIQ) Lower (more...)Pre-Open Movers 09/12: (ALDX) (QTNT) (CTIC) Higher; (SAGE) (ICPT) (HIIQ) Lower (more...)
www.streetinsider.com - September 12 at 6:17 PM
Jefferies Group LLC Begins Coverage on CTI BioPharma Corp. (CTIC)Jefferies Group LLC Begins Coverage on CTI BioPharma Corp. (CTIC)
www.americanbankingnews.com - September 12 at 9:24 AM
CTI BioPharma (CTIC) Presents At 24th Annual NewsMakers in the Biotech Industry - SlideshowCTI BioPharma (CTIC) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow
seekingalpha.com - September 11 at 6:18 PM
CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference - PR Newswire (press release)CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference - PR Newswire (press release)
www.prnewswire.com - August 31 at 10:52 PM
CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry ConferenceCTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference
finance.yahoo.com - August 31 at 4:46 AM
20 Stocks Moving In Fridays Pre-Market Session | Benzinga - Benzinga20 Stocks Moving In Friday's Pre-Market Session | Benzinga - Benzinga
www.benzinga.com - August 18 at 10:46 PM
CTI Biopharmas Pacritinib: Where We Stand Today - Seeking AlphaCTI Biopharma's Pacritinib: Where We Stand Today - Seeking Alpha
seekingalpha.com - August 14 at 6:00 PM
CTI BioPharmas (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking AlphaCTI BioPharma's (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 5:54 PM
CTI BioPharmas (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking AlphaCTI BioPharma's (CTIC) CEO Adam Craig on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 5:54 PM
Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMTEdited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:54 PM
Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMTEdited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:54 PM
CTI BioPharma Corp. (NASDAQ:CTIC) Releases  Earnings Results, Beats Estimates By $0.63 EPSCTI BioPharma Corp. (NASDAQ:CTIC) Releases Earnings Results, Beats Estimates By $0.63 EPS
www.americanbankingnews.com - August 3 at 7:02 PM
EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q2 Earnings ReportEARNINGS SUMMARY: Details of CTI BioPharma Corp. Q2 Earnings Report
www.rttnews.com - August 3 at 7:01 PM
Investor Network: CTI BioPharma Corp. to Host Earnings CallInvestor Network: CTI BioPharma Corp. to Host Earnings Call
finance.yahoo.com - August 3 at 7:01 PM
CTI BioPharma Reports Second Quarter 2017 Financial ResultsCTI BioPharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 7:01 PM
CTI BioPharma posts 2Q profitCTI BioPharma posts 2Q profit
finance.yahoo.com - August 3 at 7:01 PM
CTI BioPharma Announces First Patient Enrolled in...CTI BioPharma Announces First Patient Enrolled in...
www.benzinga.com - August 2 at 11:32 PM
CTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of PacritinibCTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of Pacritinib
www.streetinsider.com - August 2 at 11:32 PM
CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who ... - PR Newswire (press release)CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who ... - PR Newswire (press release)
www.prnewswire.com - August 2 at 6:29 PM
CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphomaCTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma
finance.yahoo.com - August 2 at 4:18 AM
CTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of Pacritinib - StreetInsider.comCTI BioPharma (CTIC) Says First Patient Enrolled in Phase 2 Trial of Pacritinib - StreetInsider.com
www.streetinsider.com - August 1 at 11:17 PM
CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with RuxolitinibCTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
finance.yahoo.com - August 1 at 3:34 AM
CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017
finance.yahoo.com - July 27 at 2:28 AM
CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, MD, to Board of Directors - PR Newswire (press release)CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, MD, to Board of Directors - PR Newswire (press release)
www.prnewswire.com - July 25 at 5:35 PM
CTI BioPharma (CTIC) Appoints Veteran Laurent Fischer, MD, to Board of Directors - StreetInsider.comCTI BioPharma (CTIC) Appoints Veteran Laurent Fischer, MD, to Board of Directors - StreetInsider.com
www.streetinsider.com - July 24 at 10:59 AM

SEC Filings

CTI BioPharma (NASDAQ:CTIC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CTI BioPharma (NASDAQ:CTIC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CTI BioPharma (NASDAQ CTIC) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.